Merck launches Phase 3 CORALreef program for PCSK9 inhibitor MK-0616

Merck launches Phase 3 CORALreef program for PCSK9 inhibitor MK-0616

Pharmaceutical giant Merck has announced the initiation of its groundbreaking Phase 3 clinical program, CORALreef, focusing on MK-0616—a novel, oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor. MK-0616 is being evaluated for the treatment of adults suffering from hypercholesterolemia. The CORALreef program marks a historic milestone as the first Phase 3 clinical program for an […]

AstraZeneca acquires oral PCSK9 inhibitors from Dogma Therapeutics

AstraZeneca acquires oral PCSK9 inhibitors from Dogma Therapeutics

Pharma giant AstraZeneca has signed a deal to acquire a preclinical oral PCSK9 inhibitor asset from Dogma Therapeutics, a portfolio company of Viva Biotech. The financial terms of the deal were not disclosed. AstraZeneca intends to take the PCSK9 inhibitor program into clinical trials in 2021 for dyslipidemia and also familial hypercholesterolemia. People having dyslipidemia, […]

Novartis to acquire The Medicines Company for $9.7bn with eye on inclisiran

Novartis to acquire The Medicines Company for $9.7bn with eye on inclisiran

Novartis acquisition of The Medicines Company : Swiss drugmaker Novartis signed a deal worth $9.7 billion to acquire US biopharma company The Medicines Company, as per the latest pharma acquisition news. As per the terms of the all-cash deal, Novartis will acquire The Medicines Company for $85.00 per share. The Medicines Company, which is headquartered […]